APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors. - Wikidata - awgldk - TriplyDB

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.

http://www.wikidata.org/entity/Q39084817

about

Onto better TRAILs for cancer treatment Principles of antibody-mediated TNF receptor activation Getting TRAIL back on track for cancer therapy TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.Symmetry Controlled, Genetic Presentation of Bioactive Proteins on the P22 Virus-like Particle Using an External Decoration Protein.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma.Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models.Caffeic acid phenethyl ester enhances TRAIL-mediated apoptosis via CHOP-induced death receptor 5 upregulation in hepatocarcinoma Hep3B cells.Key regulators of apoptosis execution as biomarker candidates in melanoma Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.An Apoptosis-Inducing Peptidic Heptad That Efficiently Clusters Death Receptor 5.IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer.Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy.Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.Developing TRAIL/TRAIL death receptor-based cancer therapies.STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.IgG-single-chain TRAIL fusion proteins for tumour therapy.Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis.A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism Promising Antineoplastic Actions of Melatonin

P2860

Q26768160-8ECA3BE8-03C8-4C5C-8BB0-209969225473 Q26796270-2F8426C6-6465-44FB-B33E-E75015157F4F Q27027460-268DFEE5-E80E-46D8-8039-79E06C455EF5 Q34557885-2C61F347-5E0F-4D94-89C5-625AB2460C5D Q35590091-34EBD252-078C-4A20-8028-F48EFEF61B72 Q36892485-FF2EFADD-007C-402F-B53C-B651B727A064 Q37012681-16DF8D05-6929-4A49-A7E3-38F0A4040226 Q37141627-CED9768E-7487-46B3-84D8-A222FBB917AB Q37492231-DECDEE42-EF05-444B-8D21-607B2871922D Q37641600-E0E44738-AC17-485A-A843-5751B02ED414 Q38340808-90973292-9A62-484B-8D4F-867F7463C446 Q38750240-27548EDD-8351-43A2-9013-E1F8EB09A244 Q38766692-8842A833-880B-47CA-9DEA-837093BD7347 Q38866722-77686864-22BD-4F7E-887A-C55CAEA16664 Q38931192-E89A22F3-B1B1-4B1B-A6F7-CD29934BAA9F Q39908453-081DAC09-5BB5-41C7-BA06-6AE3AE60D5CD Q41285625-E3D85DEC-7D76-47B7-88AC-7FBF53A75B9E Q50070105-09A4A44E-BB26-4587-B911-F21E753A41D9 Q51760860-4EB39D59-3FC1-441D-8A40-B3D5EED431D0 Q52579567-CBB4F943-2E27-4E17-AE19-21586176A57C Q53701901-4322E4A3-46F6-4BF0-8B23-4414140443E6 Q54959839-C5CCDDA6-0336-4C7F-9A4C-A8217F6E5AB1 Q54998541-13CF9241-BC58-4464-8B35-3C403B6B6D18 Q55012569-32D63CEE-9DD6-4252-84DF-0A957FA2477A Q55101408-D8CBE79E-C767-43D2-8316-78C0358A6CE1 Q57300170-16A60538-5E58-4C96-AD44-33B644CDFF71 Q58547260-CE386A68-3C77-4CFB-828B-7D6CECB2CCD4 Q58554204-EE8E7E2D-0D77-4BFE-A4C5-1024D677BF68

P2860

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.

http://www.wikidata.org/entity/Q39084817

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

APG350 induces superior cluste ...... oss-linking via Fcγ receptors.

@en

APG350 induces superior cluste ...... oss-linking via Fcγ receptors.

@nl

type

label

APG350 induces superior cluste ...... oss-linking via Fcγ receptors.

@en

APG350 induces superior cluste ...... oss-linking via Fcγ receptors.

@nl

prefLabel

APG350 induces superior cluste ...... oss-linking via Fcγ receptors.

@en

APG350 induces superior cluste ...... oss-linking via Fcγ receptors.

@nl

P1433

Q39084817-FC785C8F-F061-46A5-8DD6-34227D366129

P1476

Q39084817-44D00DB7-FF1A-47B3-9DBC-E946CCAF1DB4

P2093

Q39084817-10186874-753A-4191-9568-2BE018E072EA

Q39084817-29155B27-E150-4B90-9FAE-A203EAA7B8E5

Q39084817-42945ED3-A8BE-4521-8437-F47885E328EE

Q39084817-6289EF77-86E0-4561-8918-7D4DE43C2E15

Q39084817-74B83EEA-3976-4C22-ADC7-8A4D4020F084

Q39084817-8F1EBBD1-B801-420C-BAA2-BA107ECFE1D2

Q39084817-A5646CB8-BB89-4EB1-83FF-68D3B1370660

Q39084817-A8A3E573-69C4-48F3-B340-6C0D65A4B071

Q39084817-AE16F712-34B9-4FE6-BCD8-A0D9E0CD97D6

Q39084817-BBC31487-CB75-410B-B383-E4F3C8B1F4E8

P304

Q39084817-B8F6624D-7EF6-4E16-8EEE-3718883130EB

P31

Q39084817-C49FA133-A596-43C7-86D4-FC5C8E58E046

P356

Q39084817-13AF1B66-BB45-459A-A53E-474BE696FE32

P433

Q39084817-3B7F0671-CB22-45C3-9176-0A5AE1F05AF6

P478

Q39084817-88FEA0A2-6EBA-405C-95A6-2966F9DF321C

P50

Q39084817-66F9F5F9-7434-4BA2-B56F-89388B2B485C

P577

Q39084817-9578817D-C040-48DF-9E4D-B8391AC782E8

P5875

Q39084817-97299080-3B78-47C0-A2F0-4098A8EEF246

P698

Q39084817-E8BDBC53-593A-49D6-8205-ED1E4EA61DC7

P356

1535-7163.MCT-13-0323

P1433

Molecular Cancer Therapeutics

P1476

APG350 induces superior cluste ...... oss-linking via Fcγ receptors.

@en

P2093

Behnaz Ahangarian Abhari

http://www.w3.org/2001/XMLSchema#string

Carmen Fischer

http://www.w3.org/2001/XMLSchema#string

Christian Gieffers

http://www.w3.org/2001/XMLSchema#string

Christian Merz

http://www.w3.org/2001/XMLSchema#string

Harald Fricke

http://www.w3.org/2001/XMLSchema#string

Jaromir Sykora

http://www.w3.org/2001/XMLSchema#string

Marcus Branschädel

http://www.w3.org/2001/XMLSchema#string

Meinolf Thiemann

http://www.w3.org/2001/XMLSchema#string

Michael Kluge

http://www.w3.org/2001/XMLSchema#string

Oliver Hill

http://www.w3.org/2001/XMLSchema#string

P304

2735-2747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-13-0323

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257530646

http://www.w3.org/2001/XMLSchema#string

P698

24101228

http://www.w3.org/2001/XMLSchema#string